Daphne Koller

Daphne Koller founded Insitro to apply machine learning at scale to drug discovery, building an integrated platform that combines large-scale biological data generation (high-content imaging, single-cell transcriptomics, CRISPR screens) with advanced AI models to identify drug targets and predict therapeutic efficacy. Her probabilistic graphical model expertise from Stanford has been translated into disease biology, using machine learning to identify causal relationships between genetic variants, molecular phenotypes, and clinical outcomes. She has applied this platform to oncology programs, using AI to identify cancer patient subpopulations likely to respond to specific targeted therapies. Her work represents the vanguard of integrating machine learning with experimental biology for cancer drug discovery.